DMS Group 2024 Results: Growth and Profitability on the Rise

Diagnostic Medical Systems (DMS Group) announced a 9% increase in revenue for 2024, reaching €46.1 million. EBITDA increased significantly, from €1.7 million in 2023 to €2.7 million, an increase of 57%. Operating expense savings contributed to this performance.

Radiology and bone densitometry activities generated 78% and 22% of total revenue, respectively. Internationally, the African and Asian markets experienced significant growth, 65% and 68%, respectively. In Europe, revenue remained stable, representing 58% of total business.

A strategic action plan, #Imaging 2027, targets revenue of €70 million and EBITDA of €10 million. The group plans to intensify its efforts in innovation and international expansion.